Literature DB >> 10478902

Depression and aging: a look to the future.

C F Reynolds1, D J Kupfer.   

Abstract

Geriatric depression is widespread, affecting at least one of six patients treated in general medical practice and an even higher percentage in hospitals and nursing homes. Depression in later life has serious consequences, including patients' and caregivers' distress, amplification of disability associated with medical and cognitive disorders of later life, increased health care costs, and increased mortality related to suicide and medical illness. Despite the numerous pathways to late-life depression, as well as the complex medical and psychosocial context in which it occurs, it can be effectively diagnosed and treated. To meet the public health challenges posed by geriatric depression over the next 15 years, the major priorities for research and clinical practice must include improvement in recognizing and treating depression among elderly patients seen in the general medical sector, suicide prevention among elderly patients seen in primary care, and acceleration of response to antidepressants. Other major priorities include improving the early recognition of treatment resistance in late-life depression and developing strategies for improving the treatment response of such patients; finding maintenance treatments with long-term efficacy, especially for patients over age 70 and those who have required electroconvulsive therapy; and developing preventive strategies to reduce the liability to late-onset depression.

Entities:  

Mesh:

Year:  1999        PMID: 10478902     DOI: 10.1176/ps.50.9.1167

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  18 in total

1.  Disruption of amygdala-entorhinal-hippocampal network in late-life depression.

Authors:  Stephanie L Leal; Jessica A Noche; Elizabeth A Murray; Michael A Yassa
Journal:  Hippocampus       Date:  2017-02-07       Impact factor: 3.899

2.  Adapting problem-solving therapy for depressed older adults in methadone maintenance treatment.

Authors:  Daniel Rosen; Jennifer Q Morse; Charles F Reynolds
Journal:  J Subst Abuse Treat       Date:  2010-10-30

Review 3.  Promoting declines in the prevalence of late-life disability: comparisons of three potentially high-impact interventions.

Authors:  Vicki A Freedman; Nancy Hodgson; Joanne Lynn; Brenda C Spillman; Timothy Waidmann; Anne M Wilkinson; Douglas A Wolf
Journal:  Milbank Q       Date:  2006       Impact factor: 4.911

4.  Soluble amyloid-β levels and late-life depression.

Authors:  Ricardo S Osorio; Tyler Gumb; Nunzio Pomara
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 5.  Trauma and Aging.

Authors:  Joan M Cook; Vanessa Simiola
Journal:  Curr Psychiatry Rep       Date:  2018-09-07       Impact factor: 5.285

Review 6.  Chronic depression in the elderly: approaches for prevention.

Authors:  C F Reynolds; G S Alexopoulos; I R Katz; B D Lebowitz
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

7.  Work expectations, realizations, and depression in older workers.

Authors:  Tracy A Falba; Jody L Sindelar; William T Gallo
Journal:  J Ment Health Policy Econ       Date:  2009-12

8.  Measurement differences in depression: chronic health-related and sociodemographic effects in older Americans.

Authors:  Frances M Yang; Richard N Jones
Journal:  Psychosom Med       Date:  2008-11-03       Impact factor: 4.312

9.  White Matter Hyperintensity Accumulation During Treatment of Late-Life Depression.

Authors:  Alexander Khalaf; Kathryn Edelman; Dana Tudorascu; Carmen Andreescu; Charles F Reynolds; Howard Aizenstein
Journal:  Neuropsychopharmacology       Date:  2015-06-10       Impact factor: 7.853

10.  Lack of serotonin1B receptor expression leads to age-related motor dysfunction, early onset of brain molecular aging and reduced longevity.

Authors:  E Sibille; J Su; S Leman; A M Le Guisquet; Y Ibarguen-Vargas; J Joeyen-Waldorf; C Glorioso; G C Tseng; M Pezzone; R Hen; C Belzung
Journal:  Mol Psychiatry       Date:  2007-04-10       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.